Abstract
In the next 10 years, major changes in the pharmacotherapy of diabetes can be expected. Both the currently used groups of drugs classified as dipeptidyl-peptidase-4 blockers (gliptins) and so-called incretin mimetics (including both natural substances and incretin analoques) will be significantly expanded by up to ten new drugs.
In addition, ther completely new groups of drugs that act, for instance, via the hepatal mechanism or by influencing the metabolism of steroids will appear.